Welcome to our dedicated page for Ashland news (Ticker: ASH), a resource for investors and traders seeking the latest updates and insights on Ashland stock.
Ashland Inc. (NYSE: ASH) is a global leader in specialty chemicals and advanced additives serving industries from pharmaceuticals to sustainable construction. This page provides investors and professionals with essential updates on corporate developments, financial results, and market innovations.
Discover official press releases alongside curated analysis of Ashland's strategic initiatives in life sciences, personal care ingredients, and industrial solutions. Our repository includes updates on product launches, sustainability efforts, and operational milestones that shape the company's trajectory.
Key content categories include quarterly earnings reports, merger and acquisition activity, leadership changes, and technological breakthroughs in specialty chemicals. All materials are sourced from verified channels to ensure accuracy and relevance for decision-makers.
Bookmark this page for streamlined access to Ashland's evolving story. Check regularly for new developments that demonstrate the company's commitment to solving complex material science challenges through innovation.
Ashland reported second quarter fiscal 2025 results with sales of $479 million, down 17% year-over-year. The decline includes a 12% reduction from Portfolio Optimization initiatives and a 5% organic decrease.
Key financial metrics include:
- Income from continuing operations: $30 million ($0.63 per diluted share)
- Net income: $31 million ($0.65 per diluted share)
- Adjusted EBITDA: $108 million, down 14% from prior year
- Operating cash flow: $9 million
The company's segments showed mixed performance: Life Sciences sales fell 23% to $172 million, Personal Care decreased 14% to $146 million, Specialty Additives declined 15% to $134 million, and Intermediates dropped 8% to $37 million. Despite challenges, cost savings initiatives are on track, with Life Sciences and Personal Care maintaining EBITDA margins above 30%. The company has revised its full-year fiscal 2025 outlook due to weakening macroeconomic conditions.
Ashland Inc. (NYSE: ASH) has scheduled its second-quarter fiscal 2025 earnings release for April 30, 2025, at approximately 5 p.m. ET. The company will host a live webcast with securities analysts on May 1, 2025, at 10 a.m. ET.
Key executives participating in the presentation include Chair and CEO Guillermo Novo, CFO Kevin Willis, and several senior vice presidents leading different business segments. The webcast will feature an executive summary and detailed remarks, accompanied by a slide presentation available on the company's investor relations website.
Participants can access the call via phone through a registration link and are encouraged to dial in fifteen minutes before the scheduled start time. The webcast and supporting materials will be accessible through Ashland's Investor Relations website and will remain archived for 12 months following the live event.
Ashland has completed a $10 million expansion of its pharmaceutical manufacturing plant in Cabreúva, Brazil, with a ribbon-cutting ceremony scheduled for April 4, 2025. The investment aims to meet growing market demand for coated tablets in Latin America, where consumption grew 4.3% annually between 2019-2023, with Brazil reaching 5.7% yearly growth.
The expansion includes modernization of microbial protection equipment at the R&D laboratory in São Paulo, following previous investments in Ireland and China. The new state-of-the-art facilities enhance Ashland's capabilities in tablet coatings application, color matching, stability, and quality evaluation. Local employees received specialized training at US headquarters to ensure optimal performance.
In 2023, Ashland introduced seven new platform technologies focused on sustainable innovations in personal care, pharmaceuticals, and coatings sectors. The company has already launched several patented innovations from their Transformed Vegetable Oils and Super Wetters platforms.
Ashland Inc. (NYSE: ASH) announces its upcoming Innovation Day for analysts and investors, scheduled for May 29, 2025, at their Bridgewater, New Jersey facility. The event will showcase enhanced capabilities and expanded applications of Ashland's scalable technology platforms.
The event, running from 9:00 AM to 11:30 AM ET, will feature presentations from key leadership including Chair and CEO Guillermo Novo and Chief Technology Officer Osama Musa. Participants can attend either in person or via live webcast, with in-person attendees enjoying additional benefits including:
- Lab tours highlighting applications in Life Sciences, Personal Care, and Specialty Additives
- Direct engagement with senior leadership during Q&A sessions
- Networking opportunities with business line leaders and scientists during a luncheon
In-person activities will conclude at approximately 2:00 PM ET. The presentation materials will be available on Ashland's investor website, with replay access for 12 months following the event.
Ashland Inc. (NYSE: ASH) has completed the sale of its Avoca business to Mane on March 14, 2025. The Avoca business, which represents the final entity from Ashland's previous Pharmachem acquisition, specializes in producing sclareolide (a fragrance fixative) and offers contract manufacturing capabilities through facilities in North Carolina and Wisconsin.
While financial terms were not disclosed, the transaction marks a strategic divestment for Ashland. The deal transfers Avoca's manufacturing facilities and its workforce to Mane, whose CEO Samantha Mane expressed commitment to ingredient production through this acquisition. Squire Patton Boggs served as Ashland's legal advisor for the transaction.
Ashland Inc. (ASH) reported Q1 fiscal 2025 financial results with sales of $405 million, down 14% year-over-year. The decline includes an 11% reduction ($50 million) from Portfolio Optimization initiatives. The company reported a net loss of $165 million, or $3.50 per diluted share, compared to net income of $26 million in the prior year.
Adjusted EBITDA was $61 million, down 13% from the prior year, primarily due to Portfolio Optimization, reduced pricing, and increased expenses. The company maintains its full-year fiscal 2025 outlook, expecting sales between $1.90-2.05 billion and Adjusted EBITDA of $430-470 million.
Ashland signed a definitive agreement to sell its Avoca business to Mane and is implementing a $30 million cost reduction plan to offset stranded costs from the nutraceutical business sale.
Ashland (NYSE: ASH) has announced that its board of directors has declared a quarterly cash dividend of $0.405 per share on the company's common stock. The dividend will be paid on March 15, 2025, to stockholders of record as of March 1, 2025. The company reported 47,182,862 outstanding shares of common stock as of December 31, 2024.
Ashland Inc. (NYSE: ASH) has announced it will release its first-quarter fiscal 2025 earnings report on Tuesday, January 28, 2025, at approximately 5 p.m. ET. The company will host a live webcast with securities analysts on Wednesday, January 29 at 9 a.m. ET, featuring an executive summary and detailed remarks.
Key executives participating in the presentation include Chair and CEO Guillermo Novo, CFO Kevin Willis, and several senior vice presidents. A slide presentation will be available simultaneously on the company's Investor Relations website. Participants are encouraged to register for phone access and dial in fifteen minutes before the scheduled start time. The webcast and supporting materials will remain accessible on Ashland's website for 12 months following the live event.
Ashland Inc. (NYSE: ASH) has announced a definitive agreement to sell its Avoca business to Mane. The transaction is expected to close in Q1 2025, subject to customary closing conditions. Avoca, which represents the final entity from Ashland's previous Pharmachem acquisition, operates two production facilities in North Carolina and Wisconsin, specializing in Sclareolide (a fragrance fixative) and contract manufacturing capabilities. Squire Patton Boggs is serving as Ashland's legal advisor for this transaction.
Ingevity (NYSE:NGVT) has elected J. Kevin Willis to its board of directors, expanding the board to nine members, with eight being independent. Willis currently serves as senior vice president and CFO at Ashland Inc. (NYSE:ASH), where he oversees worldwide financial functions and participates in global strategy setting. During his 37-year tenure at Ashland, Willis has accumulated extensive experience in accounting, finance, and treasury management, including international operations. His expertise includes driving shareholder value through capital allocation planning, operating efficiencies, and business portfolio separations, notably Ashland's separation from Valvoline.
FAQ
What is the current stock price of Ashland (ASH)?
What is the market cap of Ashland (ASH)?
